X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (185) 185
Publication (18) 18
Conference Proceeding (11) 11
Book Review (4) 4
Book Chapter (3) 3
Book / eBook (2) 2
Dissertation (1) 1
Government Document (1) 1
Patent (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (88) 88
index medicus (66) 66
male (54) 54
clinical neurology (48) 48
female (48) 48
middle aged (42) 42
chemotherapy (38) 38
aged (33) 33
neurosciences (33) 33
neurotoxicity (33) 33
adult (32) 32
oncology (30) 30
cancer (27) 27
peripheral nervous system diseases - chemically induced (23) 23
risk factors (19) 19
antineoplastic agents - adverse effects (16) 16
health care sciences & services (16) 16
incidence (16) 16
peripheral neuropathy (16) 16
prospective studies (16) 16
diagnosis (15) 15
medicine & public health (15) 15
neuropathy (14) 14
greece (13) 13
neurology (13) 13
oxaliplatin (13) 13
analysis (12) 12
care and treatment (12) 12
pain medicine (12) 12
aged, 80 and over (11) 11
research (11) 11
treatment outcome (11) 11
antineoplastic agents - therapeutic use (10) 10
severity of illness index (10) 10
organoplatinum compounds - adverse effects (9) 9
peripheral nervous system diseases - physiopathology (9) 9
quality of life (9) 9
colorectal cancer (8) 8
medical research (8) 8
pathogenesis (8) 8
pharmacology & pharmacy (8) 8
review (8) 8
anesthesia & perioperative care (7) 7
case-control studies (7) 7
clinical trials (7) 7
medicine, experimental (7) 7
neural conduction - physiology (7) 7
neuroprotection (7) 7
peripheral nervous system diseases - prevention & control (7) 7
rehabilitation (7) 7
surgery (7) 7
assessment (6) 6
colorectal neoplasms - drug therapy (6) 6
depression (6) 6
electromyography (6) 6
further section (6) 6
health aspects (6) 6
medicine, general & internal (6) 6
multiple sclerosis (6) 6
neoplasms - drug therapy (6) 6
patients (6) 6
peripheral nervous system diseases - diagnosis (6) 6
peripheral nervous system diseases - epidemiology (6) 6
phase-ii trial (6) 6
prevention (6) 6
psychiatry (6) 6
treatment (6) 6
1st-line treatment (5) 5
advanced colorectal-cancer (5) 5
antineoplastic agents - administration & dosage (5) 5
artificial intelligence (5) 5
bortezomib (5) 5
colorectal-cancer (5) 5
computer science (5) 5
computer science, artificial intelligence (5) 5
disease progression (5) 5
electrophysiology (5) 5
greece - epidemiology (5) 5
medical colleges (5) 5
medicine (5) 5
medicine, research & experimental (5) 5
neurophysiology (5) 5
nursing (5) 5
paclitaxel (5) 5
paclitaxel - adverse effects (5) 5
phase-ii (5) 5
phenotypes (5) 5
risk-factors (5) 5
surveys and questionnaires (5) 5
therapy (5) 5
time factors (5) 5
young adult (5) 5
action potentials - physiology (4) 4
antineoplastic agents (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
anxiety (4) 4
autonomic nervous system (4) 4
breast-cancer (4) 4
cell line, tumor (4) 4
cell lung-cancer (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the Peripheral Nervous System, ISSN 1085-9489, 10/2019, Volume 24, Issue S2, pp. S4 - S5
Journal Article
Journal of the Peripheral Nervous System, ISSN 1085-9489, 10/2019, Volume 24, Issue S2, pp. S52 - S62
Proteasome inhibitors (PIs), especially bortezomib (BTZ), have come to the forefront over the last years because of their unprecedented efficacy mainly against... 
proteasome inhibitor‐induced neuropathy | bortezomib | peripheral neurotoxicity | peripheral neuropathy | carfilzomib | Carfilzomib | Pharmacogenetics | Bortezomib | Risk factors | Multiple myeloma | Phenotypes | Pathogenesis | DNA damage | Inflammation | Neuropathy | Peripheral neuropathy | Proteasome inhibitors | Quality of life | Neurotoxicity | Endoplasmic reticulum
Journal Article
Journal of the Peripheral Nervous System, ISSN 1085-9489, 10/2019, Volume 24, Issue S2, pp. S6 - S12
Chemotherapy‐induced peripheral neurotoxicity (CIPN) is a potentially dose‐limiting side effect of several commonly used cytotoxic chemotherapy agents. The... 
economic costs | neurotoxicity | adult | children | chemotherapy | Chemotherapy | Biological products | Cancer | Neurotoxicity | Phenotypes | Antitumor agents | Immune checkpoint | Cytotoxicity | Risk factors | Immunosuppressive agents | Quality of life
Journal Article
Journal of the Peripheral Nervous System, ISSN 1085-9489, 10/2019, Volume 24, Issue S2, pp. S74 - S85
Immune checkpoint inhibitors (ICIs) are increasingly used and are becoming the standard of care in the treatment of various tumor types. Despite the favorable... 
CTLA‐4 | pembrolizumab | immune checkpoint inhibitor | nivolumab | myositis | myasthenia gravis | demyelinating polyradiculoneuropathy | PD‐1 | peripheral neuropathy | PD‐L1 | Myasthenia gravis | Corticoids | Immune checkpoint | Intravenous administration | Demyelination | Toxicity | Immunotherapy | Myositis | Neuromuscular junctions | Myasthenia | Neuromuscular system | Movement disorders
Journal Article
Journal of the Peripheral Nervous System, ISSN 1085-9489, 10/2019, Volume 24, Issue S2, pp. S63 - S73
Vinca alkaloids, thalidomide, and eribulin are widely used to treat patients with childhood acute lymphoblastic leukemia (ALL), adults affected by multiple... 
assessment | vinca alkaloids | thalidomide | peripheral neurotoxicity | eribulin | Prevention | Alkaloids | Chemotherapy | Epidemiology | Cancer | Phenotypes | Acute lymphatic leukemia | Pathogenesis | Invasiveness | Peripheral nerves | Multiple myeloma | Breast cancer | Neuropathy | Lymphatic leukemia | Polyneuropathy | Patients | Catheters | Risk factors | Metastases | Neurotoxicity | Antiangiogenic agents | Children | Thalidomide
Journal Article
Journal of Machine Learning Research, ISSN 1532-4435, 2012, Volume 22, pp. 951 - 959
Journal Article